Navigation Links
The Outlook for Pharmaceuticals in Central Asia
Date:11/14/2011

NEW YORK, Nov. 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Outlook for Pharmaceuticals in Central Asia

http://www.reportlinker.com/p0203102/The-Outlook-for-Pharmaceuticals-in-Central-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

These reports provide a detailed analysis of four of the most populous countries in the world and the massive potential of their pharmaceutical markets. The markets of Central Asia contrast well; China and India are two of the largest pharmaceutical markets with very large economies, whilst Bangladesh and Pakistan are two of the smallest pharmaceutical markets with significantly smaller economies.

Bangladesh, China, India and Pakistan are projected to have a combined population of 3.0 billion in 2016, which will represent 79.1% of the total population of the Asia Pacific region covered by Espicom. As a percentage of the population, these four countries will have small elderly populations. However, they are projected to account for 72.4% of the total elderly population in the Asia Pacific region in 2016.

China and India are projected to have the largest and third largest GDPs in the region in 2016, respectively. Both are part of the BRICS group that represents the world's largest emerging economies, along with Brazil, Russia and South Africa. The BRICS countries are predicted to become the most dominant economies over the next few decades, which could lead to a shift in the global balance of economic power.

Bangladesh and Pakistan are projected to have the lowest and second lowest GDPs per capita in the Asia Pacific region in 2016, as these are two of the poorest countries in the world that also have large young populations. In comparison to China and India, the healthcare services of Bangladesh and Pakistan are underdeveloped, which is illustrated by limited health spending, low physician rates and high infant mortality rates.

Multinational pharmaceutical companies are increasingly looking to invest in or form partnerships in these four markets, due to the size of the potential drug consumer pool. The generic sectors in these four markets are particularly significant, and have grown rapidly in recent years. However, there still remain concerns over IP protection and its enforcement, which could deter multinational companies from entering these markets.

Highlights from the region

BANGLADESH

There is a large generic market in Bangladesh, and companies such as Square and Beximco are beginning to have success overseas. In November 2010, for instance, Beximco announced a strategic manufacturing, supply and product development agreement with the US firm, Adamis Pharmaceuticals, to launch generic drugs in the US market. However, despite the country possessing huge manufacturing capabilities which supply 96% of domestic need, the complete lack of R&D in domestic companies could affect the market, especially if companies have not evolved by the time the TRIPS agreement comes into effect.

CHINA

The Ministry of Health (MoH) has made lowering drug prices a top priority for health authorities in 2011. The National Development and Reform Commission (NDRC) implemented two rounds of drug price reductions in 2011, one in March and the other in September. Most of the drugs reduced were manufactured by multinationals, which had previously not been subject to pricing controls. In July 2011, the MoH revealed that it may introduce mandatory licensing policy to secure cheaper drugs for HIV/AIDS patients, as part of the country's universal health coverage programme. In January 2011, the MoH announced that the Essential Drugs List would be further expanded to cover nearly all government-sponsored grass-roots health institutions

INDIA

The Indian pharmaceutical industry is responsible for around 8% of world pharmaceutical production. Over the last couple of years, Indian pharmaceutical companies have been increasingly targeted by multinationals for both collaborative agreements and acquisition. During the first half of 2011, Bayer and Zydus Cadila agreed to set up a joint-venture called Bayer Zydus Pharma (BZP), for the sales and marketing of pharmaceutical products in India. BZP will operate in key segments of the Indian pharmaceutical market, with a focus on: women's healthcare, metabolic disorders, diagnostic imaging, cardiovascular diseases, diabetes treatments and oncology.

PAKISTAN

PAKISTAN's pharmaceutical market is small and equally split between multinational and domestic companies. Espicom projects the market to grow at a fairly high single-digit CAGR in dollar terms during the forecast period. By 2016, it will be the 11th largest pharmaceutical market in the Asia Pacific region covered by Espicom. The pharmaceutical market is dominated by locally manufactured pharmaceuticals, predominantly generic drugs, which meet around 90% of country's needs in 2011. Imported retail medicaments account for the remainder of the market, although manufacturers rely heavily on imported raw materials for production. Multinational companies account for around half of the market by value, although local producers have a far greater share in terms of volume.

To order this report:

: The Outlook for Pharmaceuticals in Central Asia

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
2. July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bells Palsy and Heart Valve Repair
3. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
4. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
5. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
6. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
7. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
8. Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook
9. Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook
10. Stryker Updates Expected 2009 Results and Provides 2010 Outlook
11. Beckman Coulter Affirms 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Calif. , Feb. 27, 2017  Titan ... therapeutics for the treatment of select chronic diseases ... today announced that the U.S. Food & Drug ... the ropinirole implant Investigational New Drug Application (IND) ... of the clinical study pending submission of the ...
(Date:2/28/2017)... TRIANGLE PARK, N.C. , Feb. 28, 2017 ... that Martine Rothblatt , Ph.D., Chairman and Chief Executive ... on the company,s business at the Cowen and Company 37 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:2/28/2017)... This report provides all the information you require to ... since 2010. Download the full report: ... Alliance since 2010 report provides an in-depth insight into ... life sciences companies. On demand company reports ... most up to date deal and company data. ...
Breaking Medicine Technology:
(Date:2/27/2017)... , ... February 27, 2017 , ... ... Shamanic Healing and Spiritual Awakening, is happy to announce her “Spring Rejuvenation ... and body, these individual customized retreats offer the winter-weary soul an excellent opportunity ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Orange ... is a chronic inflammatory gum condition that occurs when the bacteria in plaque infect ... also referred to as a scaling and root planing or SRP, and can include ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric ... Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount ... 800 customers and 2,250 RCEs at the time of acquisition. In the three ...
(Date:2/27/2017)... New Jersey (PRWEB) , ... February 27, 2017 , ... ... highest cancer rates, among all types and genders. And the need for advanced services ... by RWJ and its top-rated cancer care program, in collaboration with their non-profit partners ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based in ... Palo Alto, is proud to announce an important upgrade to its geographic information pages, ... care close to home, and by having city-specific pages, NuevaCare is answering that information ...
Breaking Medicine News(10 mins):